NYXH Nyxoah SA
1.280EUR+2.24%Mkt Cap: 141.69M $P/E: —Today
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for …
Industry Peers
Medical DevicesKey Statistics
Company
Market Cap141.69M USD
Enterprise Value89.45M USD
Revenue (TTM)23.55M USD
Gross Profit6.88M USD
Net Income (TTM)-97.92M USD
Revenue/Share0.49 EUR
Last Price1.280 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees153
CountryBE
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.53
PEG—
EV/EBITDA-0.99
EV/Revenue3.80
P/S5.64
P/B1.45
EPS (TTM)-2.19
EPS (Forward)-0.47
52W Range
1.1403% of range6.360
52W High6.360 EUR
52W Low1.140 EUR
Profitability
Gross Margin63.13%
Oper. Margin-268.25%
EBITDA Margin0.00%
Profit Margin-899.05%
ROE-183.36%
ROA-76.04%
Growth
Revenue Growth472.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-74.98M USD
CapEx (TTM)4.10M USD
FCF Margin-212.62%
FCF Yield-35.33%
Net Debt-41.08M USD
Net Debt/EBITDA0.46
Balance Sheet
Debt/Equity0.82
Current Ratio2.38
Quick Ratio2.28
Book Value/Sh0.83 EUR
Cash/Share0.98 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.733 EUR
Upside (mean)+347.9%
Target Range2.000 EUR – 9.600 EUR
2.000+347.9% to mean9.600
# Analysts3
Ownership
Shares Out.101.84M
Float50.88M
Insiders33.19%
Institutions30.87%
Technical
SMA 501.336 (-4.2%)
SMA 2002.449 (-47.7%)
Beta0.96
S&P 52W Chg14.58%
Avg Vol (30d)241.50K
Avg Vol (10d)225.59K
Technical Indicators
RSI (14)48.3
MACD-0.0377
MACD Signal-0.0374
MACD Hist.-0.0003
BB Upper1.440 EUR
BB Middle1.287 EUR
BB Lower1.134 EUR
BB Width23.77%
ATR (14)0.0825 EUR
Vol Ratio (20d)0.53x